Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.31 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 5/20 | 0.30 |
| ▸ | CES2 | O00748 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL866444 | 0.92 | FAAH (0.34) | FAAHOXER1CES1CES2MEN1 | |
| SCHEMBL865199 | 0.82 | — | — | |
| SCHEMBL25307541 | 0.80 | PLA2G4A (0.33) | FAAHOXER1CES1CES2MEN1 | |
| SCHEMBL865735 | 0.79 | CA1 (0.35) | MEN1KMT2A | |
| SCHEMBL377071 | 0.78 | FAAH (0.32) | FAAHOXER1CES1CES2MEN1 | |
| SCHEMBL8743995 | 0.78 | FAAH (0.31) | FAAHOXER1CES1CES2MEN1 | |
| SCHEMBL565341 | 0.78 | LMNA (0.53) | OXER1MEN1CYP1A2KMT2AHSD17B10 | |
| SCHEMBL1028076 | 0.76 | OXER1 (0.30) | FAAHOXER1 | |
| SCHEMBL3971918 | 0.76 | ALDH1A1 (0.46) | FAAHOXER1 | |
| SCHEMBL9935032 | 0.76 | ALDH1A1 (0.45) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023174773-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| US-10208031-B2 | Photocrosslinkable materials comprising alicyclic group | ROLIC AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-20170362381-A1 | THERMALLY STABLE ALIGNMENT MATERIALS | ROLIC AG (CH) | 2017-12-21 | — | — | US | disclosed |
| EP-1966119-B1 | PHOTOCROSSLINKABLE MATERIALS | ROLIC AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| EP-2152660-B1 | PHOTOCROSSLINKABLE MATERIALS COMPRISING ALICYCLIC GROUP | ROLIC AG (CH) | 2016-05-11 | — | — | EP | disclosed |
| US-8969552-B2 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2439203-B1 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBVIE DEUTSCHLAND (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8557922-B2 | Photocrosslinkable materials | ROLIC AG (CH) | 2013-10-15 | — | — | US | disclosed |
| EP-1812416-B1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-8486984-B2 | Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO., KG (DE) | 2013-07-16 | — | — | US | disclosed |
| EP-1809598-A1 | AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-07-25 | — | — | EP | disclosed |
| EP-1807392-A1 | 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR | Abbott GmbH & Co. KG (DE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007071091-A1 | PHOTOCROSSLINKABLE MATERIALS | ROLIC AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006040177-A1 | 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR | ABBOTT GMBH & CO.KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040180-A1 | AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040178-A1 | ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO.KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040176-A1 | AZABICYCLOHEPTYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040179-A1 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| US-4895587-A | Haloacetamide compounds, process for production thereof, and use thereof as herbicide | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1990-01-23 | — | — | US | disclosed |
| EP-0206251-B1 | HALOACETAMIDE COMPOUNDS, PROCESS FOR PRODUCTION THEREOF, AND USE THEREOF AS HERBICIDE | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208031-B2 | Photocrosslinkable materials comprising alicyclic group | DDC, ALAD, DYNC1LI1 | FAAH 434/4885OXER1 3309/4885CES1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.